What exactly are you talking about?

One of the difficult aspects of an illness is learning the new vocabulary behind it. Occasionally, in the blog, we decipher some of the phrases you might hear and try to make the information more clear. For today – it’s disease status.


It is how doctors refer to the progression of your cancer and it's response to treatment using the following terms:


De Novo: In cancer, the first occurrence of cancer in the body.

Newly diagnosed/not previously treated: Some experimental treatments are designed to be "first line", that is, the first treatment to be given after diagnosis. For this reason, some trials may only enroll patients who have not yet had their cancer treated. Also referred to as De Novo.

Complete Remission (CR): The disappearance of all signs of cancer in response to treatment. This does not always mean the cancer has been cured. Also called a complete response.

Partial Remission (PR): The term used when a cancer has shrunk in size (usually at least in half) but has not totally disappeared. The cancer can still be detected, and other treatments may be recommended. Also called a partial response.

Relapse: The return of signs and symptoms of cancer after a period of improvement.

Refractory: Cancer that does not respond to treatment. The cancer may be resistant at the beginning of treatment or it may become resistant during treatment. Also called resistant cancer.

Stable disease: Cancer that is neither decreasing nor increasing in extent or severity.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap